How to plan a stem cell clinic Chandler visit

Choose the easiest route

Dobson Road gives Chandler drivers a direct street route to the office. Drivers from Ocotillo or Fulton Ranch can follow Dobson north.

From Historic Downtown, take Arizona Avenue south to Pecos, then west to Dobson. Leave spare travel time so you arrive settled for the exam.

Save the full address where you can read it before leaving. If driving hurts, ask someone else to take you.

Bring what the clinician needs

Carry your medicine names, past reports, and dates of earlier care. A short note about what helped can save time during the visit.

Pick one familiar activity that you want to regain. This gives the examiner a clear goal for discussing your choices.

Ask what the visit will cover

Expect to describe when soreness started and the motions that worsen it. The examiner may test your movement and strength around the sore area.

Ask the clinic whether an X-ray or a surgeon's opinion is needed first. Ask about recovery time before choosing any procedure.

Write down the next steps

Before leaving, note the likely cause and each choice discussed. Include home care, expected recovery, cost, and the next check-in.

Don't agree to care until each step makes sense to you. At 1100 S. Dobson Rd., Suite 210, Chandler, AZ 85286, QC Kinetix offers consultations about regenerative care, meaning a non-surgical shot prepared from blood or marrow.

Sources

1. The International Society for Cell & Gene Therapy position statement holds that the acronym MSC should mean mesenchymal STROMAL cells and should only be called stem cells where rigorous in vitro and in vivo evidence of stemness exists for that specific preparation.

   Viswanathan S, et al. — Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy, 2019. DOI: 10.1016/j.jcyt.2019.08.002.

2. Mesenchymal stromal cells make up only about 0.001 to 0.01 percent of the nucleated cells in bone marrow, so the harvesting and processing technique - aspiration site, syringe size, centrifuge speed and time - materially determines what ends up in the syringe, and no consensus protocol exists.

   Jeyaraman M, et al. — Impact of the Process Variables on the Yield of Mesenchymal Stromal Cells from Bone Marrow Aspirate Concentrate. Bioengineering (Basel), 2022. DOI: 10.3390/bioengineering9020057.

3. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use.

   US Code of Federal Regulations, Title 21 — 21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act. , 2004.

4. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.